Literature DB >> 9737302

Carcinoid tumour.

M E Caplin1, J R Buscombe, A J Hilson, A L Jones, A F Watkinson, A K Burroughs.   

Abstract

Carcinoid tumours are often indolent asymptomatic tumours. However, a small but significant proportion are malignant and difficult to manage. Multiple endocrine neoplasia type 1 (MEN-1) may be associated with carcinoid tumours and should therefore be considered in the investigation of these patients. This review puts into context the use of newer imaging modalities, including octreotide scintigraphy. The therapeutic treatment options are discussed, including the use of octreotide, the role of receptor-targeted therapy, hepatic-artery embolisation, and the arguments against chemotherapy. We review the need for careful patient selection when considering curative and palliative surgery, including liver transplantation. We conclude that there are now better diagnostic tools and therapeutic options available for those patients with malignant carcinoid tumours, and that these patients are best managed by a multidisciplinary approach. Earlier detection and treatment of these tumours should lead to improved quality of life and survival, which, ideally, should be assessed in formal trials.

Entities:  

Mesh:

Year:  1998        PMID: 9737302     DOI: 10.1016/S0140-6736(98)02286-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  78 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

Review 2.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

3.  Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene.

Authors:  W Stewart; J P Traynor; A Cooke; S Griffiths; N F Onen; M Balsitis; A A Shah; M Upadhyaya; E S Tobias
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

4.  Multiple pulmonary neoplasia positive for thyroglobulin.

Authors:  I Torres; A Garcia; M J Palomo; M Aguilar
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

5.  99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.

Authors:  A Hubalewska-Dydejczyk; K Fröss-Baron; R Mikołajczak; H R Maecke; B Huszno; D Pach; A Sowa-Staszczak; B Janota; P Szybiński; J Kulig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

6.  [Diagnosis of ileal carcinoid with contrast enhanced ultrasonic diagnosis].

Authors:  Steffen Rickes; Christine Uhle; Holger Neye; Daniel Ensberg; Peter Rauh
Journal:  Med Klin (Munich)       Date:  2009-07-15

Review 7.  The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

8.  Carcinoid and neuroendocrine tumors of the colon and rectum.

Authors:  T Philip Chung; Steven R Hunt
Journal:  Clin Colon Rectal Surg       Date:  2006-05

9.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

Review 10.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.